Discover What's New

Press Releases

  • Cumberland, R.I. (May 6, 2013) – Onset Dermatologics, a PreCision Dermatology Company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of Aurstat® Anti-Itch Hydrogel. Aurstat® is a treatment for itch, including itch related to atopic dermatitis. Atopic dermatitis is also called eczema. Aurstat® contains HOCl (hypochlorous acid) as a preservative.

  • NEW YORK, NY.--(BUSINESS WIRE, February 13, 2013)-- PreCision Dermatology, Inc., a leader in developing and commercializing novel, prescription and physician dispensed products for improving skin health, announced today the appointment of Robert Moccia to the newly created position of Chief Operating Officer. In that role, all operating functions of PreCision will report to Mr. Moccia. In addition, Mr Moccia will serve as the President of Onset Dermatologics, LLC, a wholly owned subsidiary of Precision Dermatology.

  • Significantly Expands Market Position of Onset Dermatologics in Clinical Dermatology

    NEW YORK, NY (April 30, 2012) – PreCision Dermatology, a leading producer and marketer of innovative dermatological and skin care therapies, today announced the acquisition of the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with a range of branded prescription dermatology products, including the mid-potency topical steroid Locoid®, as well as Minocin® and Tretin-X™. The products will be marketed by Onset Dermatologics, which is the prescription dermatology subsidiary of PreCision Dermatology. The move significantly expands Onset's offering of high quality branded products designed to provide dermatologists, physician assistants and nurse practitioners with superior solutions to their patients' needs.

  • New Data Confirm Clinical Efficacy of Aurstat® Hydrogel in Reducing Itch Related to Atopic Dermatitis

    CUMBERLAND, R.I. (February 28, 2012) – Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of Aurstat® Kit. Aurstat® Kit contains Aurstat® Skin & Wound Hydrogel and HylatopicPlus® Cream. Aurstat® Hydrogel is a treatment for itch, including itch related to atopic dermatitis and eczema. Aurstat® contains the key components of a bleach bath in an easy to use topical formulation. Bleach baths have been proven to improve the symptoms of atopic dermatitis1. HylatopicPlus® is a ceramide-rich, non-steroidal prescription therapy which incorporates hyaluronic acid to deliver a blend of physiologic lipids to restore healthy skin barrier function in patients with atopic dermatitis. The two products are packaged together for patient convenience.

  • Hylatopic® Becomes the Most Prescribed Skin Barrier Repair Therapy Brand

    CUMBERLAND, R.I. (November 14, 2011) – Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus Cream in a convenient 450 gram jar with pump dispenser. HylatopicPlus Cream is indicated to manage and relieve the burning, itching and pain experienced with various types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation dermatitis. HylatopicPlus Cream also helps alleviate dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

  • CUMBERLAND, R.I. (August 22, 2011)—Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of HylatopicPlus® Cream. HylatopicPlus® Cream is indicated to manage and relieve the burning, itching and pain experienced with various types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation dermatitis. HylatopicPlus® Cream also helps alleviate dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

  • CUMBERLAND, R.I., Feb. 8, 2011 (GLOBE NEWSWIRE) -- Onset Dermatologics, a PreCision Dermatology company and an emerging leader in the development and commercialization of novel, patent-protected products for the treatment of skin disorders, today announced that several clinical posters about Onset Dermatologics' products were presented during the Annual Meeting of the American Academy of Dermatology in New Orleans, LA from February 4th - 8th. Two of the studies validated the company's HylatopicPlus® Emollient Foam as an effective therapy for treating patients with atopic dermatitis and impaired skin barrier function. Two additional poster presentations confirmed the tolerability and patient preference for BenzEFoam® (benzoyl peroxide) Emollient Foam 5.3% for the treatment of acne.

  • Cumberland, RI (February 4, 2011)—Onset Therapeutics, a PreCision Dermatology company and a leader in the development and commercialization of novel, prescription products for the treatment of skin disorders, today announced that it has changed its corporate name to Onset Dermatologics. The name change has been undertaken to emphasize the Company's focus on dermatology and on delivering advanced topical therapies that patients prefer. Onset Dermatologics will be exhibiting its full line of products at Booth # 2170 at the upcoming American Academy of Dermatology Annual Meeting taking place in New Orleans, LA from February 4th - 8th.

  • Cumberland, RI (December 1, 2010) — PreCision Dermatology Inc., a company focused on developing, manufacturing, acquiring and marketing a broad portfolio of innovative dermatology products, today announced it was formed as the result of the spin-out of Onset Therapeutics, a wholly owned subsidiary of Collegium Pharmaceutical, Inc. PreCision Dermatology also announced the close of a Series A financing led by life science private equity investor Essex Woodlands. Existing Collegium Pharmaceutical investors including Boston Millennia Partners, Frazier Healthcare and Westfield Capital Management also participated in the financing.